Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to an androgen receptor targeting moiety via linker.

Ocean University of China has identified imidazothiazole derivatives acting as MAPK-interacting kinase 1 (MNK1) and MNK2 inhibitors.

Researchers at Origenis GmbH have patented pyrazolotriazine derivatives acting as inhibitors of cyclin-dependent kinase (CDK), particularly CDK2 and CDK9.

Research at Neo Cremar Co. Ltd. has led to the development of peptides acting as growth/differentiation factor 8 (GDF-8; myostatin) inhibitors.

Transcriptional enhancer factor TEF (TEAD) inhibitors are described in a Genentech Inc. patent as potentially useful for the treatment of cancer.

The University of Sydney has patented P2X7 receptor antagonists reported to be useful for the treatment of stroke, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer’s disease, Huntington’s disease, atherosclerosis, diabetic retinopathy and myocardial infarction, among others.

New isoindolines acting as mismatch repair endonuclease PMS2 inhibitors have been reported in a Neophore Ltd. patent as useful for the treatment of cancer.

Geode Therapeutics Inc. and Xtalpi Inc. have jointly developed phosphatidylinositol 3-kinase γ (PI3Kγ) inhibitors reported to be useful for the treatment of cancer.

Recent Kallyope Inc. patents report AMP-activated protein kinase (AMPK) activators potentially useful for the treatment of allergy, cancer, depression, diabetes type 2, nutrition disorders, obesity, psoriasis, inflammatory bowel disease, metabolic syndrome, nonalcoholic steatohepatitis, Alzheimer’s and Parkinson’s disease, among others.

Research at Kumquat Biosciences Inc. has led to the development of Hetero-atom containing compounds described as tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and (PTPN2; TCPTP) inhibitors and reported to be useful for the treatment of cancer.